Thomas P. Cappola, M.D., Sc.M.
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
Penn Cardiovascular Institute
11-102 Translational Research Center
3400 Civic Center Boulevard
Philadelphia, PA 19104
11-102 Translational Research Center
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-0805
Fax: 215-615-0828
Fax: 215-615-0828
Publications
Links
Search PubMed for articles
Penn Health Profile
Cardiovascular Division Faculty
Penn CVI/IDOM Complex Genomics Initiative
Search PubMed for articles
Penn Health Profile
Cardiovascular Division Faculty
Penn CVI/IDOM Complex Genomics Initiative
Education:
A.B. (Chemistry)
Princeton University, 1991.
M.D. (Medicine)
Harvard Medical School, 1995.
Sc.M. (Clinical Investigation )
Johns Hopkins Bloomberg School of Public Health, 2004.
Permanent linkA.B. (Chemistry)
Princeton University, 1991.
M.D. (Medicine)
Harvard Medical School, 1995.
Sc.M. (Clinical Investigation )
Johns Hopkins Bloomberg School of Public Health, 2004.
Description of CVI Expertise
CVI Program Unit(s):Myocyte Biology / Heart Failure
Biotechnology / Nanomedicine / Imaging
CVI Research Description:
My group studies mechanisms of human cardiac remodeling using genomics, biomarkers, and proof-of-concept studies of novel therapeutics.
Current projects include:
1) Transcriptional Genomics of Human Heart Failure:
A novel approach that determines transcription factor activity in the failing human heart by integrating gene expression data, promoter sequence data, and transcription factor response element data. Results from these experiments have suggested a role for specific Forkhead (FOX) transcription factors in remodeling, which have become the major biologic focus of our research.
2) The Penn Heart Failure Study (PHFS):
A prospective observational cohort study of subjects with wide range of heart failure whose broad aim is to detect genomic and proteomic modifiers of heart failure progression. Biomarker and SNP/Haplotype association studies are currently underway in this cohort of ~800 subjects.
Selected Publications
Testani JM, McCauley BD, Chen J, Coca SG, Cappola TP, Kimmel SE: Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. J Card Fail 17(12): 993-1000, Dec 2011.Testani JM, Coca SG, Shannon RP, Kimmel SE, Cappola TP: Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials. Eur J Heart Fail 13(11): 1224-30, Nov 2011.
Barth AS, Kumordzie A, Frangakis C, Margulies KB, Cappola TP, Tomaselli GF: Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure. Circ Cardiovasc Genet 4(5): 475-83, Oct 2011.
Jessup M, Greenberg B, Mancini D, Cappola TP, Pauly DF, Jaski B, Alex Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ: CUPID - a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) in patients with advanced heart failure. Circulation 124(3): 304-313, July 2011.
Ky B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB, Cappola TP: The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol 58(4): 395-401, July 2011.
Testani J, Cappola TP, Brensinger C, Shannon RP, Kimmel S: Interaction between loop-diuretic associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol 58(4): 375-382, July 2011.
Trivedi CM, Cappola TP, Margulies KB, Epstein JA: Homeodomain only protein X is down-regulated in human heart failure J Mol Cell Cardiol 50(6): 1056-8, June 2011.
Testani JM, Cappola TP, McCauley BD, Chen J, Shen J, Shannon RP, Kimmel SE: Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization Am Heart J 161(5): 944, May 2011.
Ky, French BC, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AHB, Fang JC, Boxer R, Sweitzer NK, Levy W, Goldberg LR, Jessup M, Cappola TP: High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4(2): 180-187, Mar 2011.
Cappola TP, Matkovich SJ, Wang W, van Booven D, Li M, Wang W, Qu L, Sweitzer NK, Fang J, Reilly MP, Hakonarson H, Nerbonne JM, Dorn II GW: A loss-of-function DNA sequence variant in CLCNKA implicates the cardio-renal axis in inter-individual heart failure risk variation. Proc Natl Acad Sci USA 108(6): 2456-61, Feb 2011.
| Protocol | Title | Status |
|---|---|---|
| 804768 | Treatment of Preserved Cardiac Function Heart Failure with Aldosterone-antagonist (Amended Protocol, Version 1.7, June 04, 2009) | Recruiting |
| 805585 | Warfarin versus Aspirin in Reduced Cardiac Ejection | Recruiting |
| 707391 | Penn Heart Failure Study (Zanthine Oxidase, Myocardial Genomics, and Heart Failure) | Recruiting |